Celmatix Appoints Women’s Health Pioneer Dr. Bart CJM Fauser to Chairmanship of Scientific Advisory Board and Newly Formed Clinical Trial Steering Committee
Fauser appointment builds on continued progress of lead AMHR2 agonist program. Celmatix lead AMHR2 agonist compound achieves in vivo PK/PD milestone. Dr. Fauser, one of the most cited investigators in reproductive health, brings deep expertise in ovarian stimulation and pathophysiology of ovarian function to Celmatix advisory board and trial committee. One of the first to … [Read more…]
